Improved in vivo Protein Expression and Durability Using dbDNA Delivered With Sartorius Non Viral Delivery Solutions

Gene Therapy approaches have historically relied on viral delivery systems, predominantly Adeno-Associated Virus, but drawbacks include limited payload capacity, complex manufacturing processes, and anti-vector immune responses that can limit in vivo efficacy. Non-viral DNA and RNA approaches offer compelling alternatives, yet their broader application has been hindered by lower delivery efficiency compared with viruses, which have naturally evolved highly effective routes into cells.

Effective non‑viral delivery systems depend not only on the route of administration and mechanisms of cellular uptake, but critically, on the selection of an appropriate DNA vector. Whether polymer‑based, liposomal, or lipid‑nanoparticle formats, these delivery platforms are continuously advanced and optimized at Sartorius to enhance efficacy, specificity and targeting. 
Enzymatically produced DNA has emerged as an alternative to plasmid-based vectors, offering advantages in manufacturing and biological performance. Touchlight has developed a portfolio of DNA molecules optimized for any size payload and compatible with all gene therapy and gene editing platforms